Feb. 17, 2021
Here is the article.
New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital: Soligenix (NASDAQ: SNGX) continues to build excitement for its SGX301 candidate following strong Phase 3 data and commercialization plans. The company recently held an investor webcast to further explain the company's plans for commercializing its ground-breaking SGX301 candidate for the treatment of cutaneous T-cell lymphoma (CTCL).
Here are some key takeaways from the commercialization Q&A:
1. Soligenix will commercialize SGX301 in the U.S. on its own
During the presentation, the company noted that after conducting necessary due diligence and simulating different routes to commercialization, it was determined that a partnership would not be the best solution for shareholders. The licensing landscape and CTCL's small, orphan market were the key drivers behind the decision. Considering that the average biopharmaceutical licensing deal, a Phase 3 licensor will typically retain no more than 40% of the product's value, it did not make sense to give up so much value when the market is small and highly specialized to begin. However, Soligenix CEO Dr. Chris Schaber noted the company continues discussions regarding partnerships for ex-U.S. rights to SGX301.
My purchase history
No comments:
Post a Comment